The Inhibrx pickup gives Sanofi access to INBRX-101, a human recombinant protein that is being investigated in patients with a rare disease known as alpha-1 antitrypsin deficiency.
How biotech companies are standing out during JPM Week
The discovery collab between Lilly and Prism, worth north of $600 million, promises to yield fresh targets that are readily druggable with small molecules.
Merck acquires preclinical biotech Caraway Therapeutics for up to $610M
Caraway Therapeutics brings three preclinical programs in Parkinson’s and rare diseases to Merck, which is putting down $610 million total for the deal.
Legend Biotech exec details $100M lung cancer treatment deal with Novartis
Legend’s subsidiary is licensing LB2102 and other potential CAR-T cell therapies targeting Delta-like ligand protein 3 to Novartis for $100 million upfront with the potential to receive up to $1.1 billion in milestone payments.
Celldex’s lead asset shows promise in 2 skin conditions
Celldex’s CSU, PN trials represent not only strong datasets but suggest barzolvolimab’s ‘pipeline-in-a-product potential’ in other mast cell-driven diseases.
Asthma-focused Aiolos Bio takes aim at Tezspire, launches with $245M raise